Posts Tagged ‘GLP-1 agonists’

News from Lilly about orforglipron this week points to what might be the next big development for GLP-1 medicines. The company announced topline results for a weight maintenance study of orforglipron and this first glimpse has us thinking that maintain might be the magic word in obesity care next year. The topline come from the […]

Truveta this week published data that reveals striking growth in the use of GLP-1s by women with PCOS (polycystic ovary syndrome). Prescriptions for semaglutide or tirzepatide have risen by more than 700% in women with PCOS, according to their analysis. So don’t think that this is slipping right by the bean counters at drug benefit […]

The attention that goes daily to the subject of preserving muscle and its importance is off the chart. Just this week a call to action about muscle loss in diabetes and a new systematic review on the effects of resistance exercise on cognitive function are demanding our attention. It is clear that preserving muscle as […]

As the world is coming around to the understanding that public health policy cannot neglect the need for obesity treatment, a question hangs in the air. What does this mean for obesity prevention strategies? This question – together with fast-changing market realities – begs another question. Will prevention policy or market dynamics reduce obesity more? […]

This is huge news and we’ve been waiting for it a very long time. For the first time ever, the World Health Organization (WHO) is embracing obesity treatment in a new global guidance issued yesterday. From the head of WHO, Director-General Tedros Adhanom Ghebreyesus, came words we wondered if we would ever hear: “Our new […]

A new research letter in JAMA tells us that more new mothers are using GLP-1s for weight management. The rise of use in this context is dramatic – roughly 500% between 2022 and 2024. Note that these data come from Denmark. There, we estimate the per capita use of GLP-1s for obesity is somewhat less […]

The sprint to the finish for orforglipron is picking up pace with a pivotal trial in obesity and diabetes published yesterday in The Lancet. Things are looking good for this relatively simple GLP-1 agonist in a tablet. The presentation of these results from ATTAIN-2 were a highlight of ObesityWeek earlier this month, but having this […]

Anyone who thought this would be a passing thing was way off the mark. As prices of GLP-1 medicines are falling, their use is rising. As Stat News notes, we now have more people using these medicines than the entire population of Texas. This rising trend occurs against a background of costs that are still […]

A year ago, we had these wonderful new obesity medicines – semaglutide and tirzepatide – and nobody could get them. Demand had outstripped supply and we had a shortage. Earlier this year, the supply shortage for both drugs resolved, but now we face the same situation because of a different shortage. There is a shortage […]

We are most accustomed to technology bringing economic disruption. Three decades ago, it was the internet. Then smartphones and social media. Now, we obsess about the effects of artificial intelligence. But a strong case is building that obesity medicine is becoming an economic disruptor on a scale that is equal or greater than any of […]